Rotigaptide in Endothelial Dysfunction?

N/ACompletedNCT07192744

University of Edinburgh12 enrolled

Overview

Arterial occlusion can lead to tissue ischemia and, if prolonged, end organ infarction. Clinical and experimental data would suggest that restoration of blood flow might trigger additional injury beyond that induced by the ischemia alone, so called Ischemia Reperfusion (IR) injury. IR injury impairs endothelial function through a mechanism that may involve intercellular gap junctions. Rotigaptide (ZP-123) is an anti-arrhythmic drug promoting intercellular coupling by increasing gap junction conductance. We intend to test the hypothesis that rotigaptide protects the forearm arterial circulation from IR-induced endothelial dysfunction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Ischaemic Heart Diseases

Interventions

Forearm vascular studyPROCEDURE

Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy males between 18-65 years of ages, non-smokers. Exclusion Criteria: * Any concurrent illness or chronic medical condition. Concurrent use of vasoactive medication. Smoking history.

Locations (1)

University of Edinburgh, 49 Little France Crescent

Edinburgh, United Kingdom

Outcomes

Primary Outcomes

Change in forearm blood flow after ischaemia reperfusion with or without co-infusion of Rotigaptide

Time frame: 20 fixed timepoints throughout the study up to 4 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.